A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

Exclusion criteria

• . Allergic constitution, such as those with a known history of allergies to two or more drugs or foods, or those with a history of allergies to experimental drugs or excipients;
• . Subjects with difficulty swallowing tablets and special dietary requirements who cannot accept a unified diet;
• . Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting;
• . Subjects who have undergone surgery within 30 days prior to screening, or plan to undergo surgery during the study;
• . Individuals with a history of paroxysmal sleep disorder, obstructive sleep apnea, complex sleep behavior (such as dream walking, driving in dreams, etc.), severe unconscious hypoglycemia, stroke, epilepsy, and other psychiatric disorders (including anxiety, depression, etc.), convulsive diseases, and sudden onset of illness;
• . Known to have QT prolongation or congenital QT syndrome or screening period electrocardiogram showed QTc interval (QTcF)\>450 msec in males and\>470 msec in females（QTcF= QT/(RR\^0.33)）;
• . Those who are positive in any index screening of hepatitis B virus surface antigen, hepatitis C virus antibody, Treponema pallidum-specific antibody, and human immunodeficiency virus antibody;
• . Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;